Peptide molecules are large and polar — the GI tract digests them like protein. Hence: research goes parenteral, and oral formats are a separate chemistry problem.
Stomach and gut enzymes digest peptides — that is their job.
Gut epithelium admits small nonpolar molecules; large peptides do not pass.
First-pass metabolism destroys what survived the GI tract.
Permeation enhancers, enzyme inhibitors, novel excipients — active research directions. Oral semaglutide (Rybelsus) is the rare clinical example. In the research market vials dominate.
In clinics — rare exceptions (Rybelsus). In the research market — vials are the standard.
For most peptides — single-digit percentages.